Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This trial is main evaluate the efficacy and safety of pembrolizumab combined with
chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic
head and neck squamous cell carcinoma